Gangtok Chronicle

Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

 Breaking News
  • No posts were found

Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

February 21
18:57 2024
Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

DelveInsight’s, “Multiple Myeloma Pipeline Insights 2024” report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Multiple Myeloma Pipeline Report

  • DelveInsight’s Multiple Myeloma pipeline report depicts a robust space with 75+ Multiple Myeloma companies working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
  • The leading Multiple Myeloma Companies working in the market include CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
  • Promising Multiple Myeloma Pipeline Therapies in the various stages of development include TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.
  • December 2023: Genentech Inc. announced a study of Phase 1 clinical trials for Cevostamab, Tocilizumab, Pomalidomide, Daratumumab and Dexamethasone. This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
  • December 2023: AbbVieannounced a study of Phase 3 clinical trials for Pomalidomide, Dexamethasone and Venetoclax. A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
  • December 2023: Regeneron Pharmaceuticals announced a study of Phase 1 clinical trials for Linvoseltamab, Daratumumab, Carfilzomib, Bortezomib and Isatuximab. The study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after multiple prior therapies and needed to be treated again.

 

Request a sample and discover the recent advances in Multiple Myeloma Treatment Drugs @ Multiple Myeloma Pipeline Outlook Report

 

The Multiple Myeloma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Multiple Myeloma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Multiple Myeloma clinical trial landscape.

 

Multiple Myeloma Overview

Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal immunoglobulins. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.

 

Find out more about Multiple Myeloma Treatment Landscape @ Drugs for Multiple Myeloma Treatment

 

Multiple Myeloma Emerging Drugs Profile

  • Zevorcabtagene Autoleucel: Carsgen Therapeutics
  • Descartes 08: Cartesian Therapeutics
  • GC012F: Gracell Biotechnology Shanghai Co., Ltd.
  • CID-103: CASI Pharmaceuticals
  • STI-1492: Sorrento Therapeutics

 

Multiple Myeloma Pipeline Therapeutics Assessment

There are approx. 75+ key Multiple Myeloma companies which are developing the Multiple Myeloma therapies. The Multiple Myeloma companies which have their Multiple myeloma drug candidates in the most advanced stage, i.e Registered include Carsgen Therapeutics.

 

DelveInsight’s Multiple Myeloma pipeline report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Multiple Myeloma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Multiple Myeloma Pipeline Therapies @ Multiple Myeloma Clinical Trials Assessment

 

Scope of the Multiple Myeloma Pipeline Report

  • Coverage- Global
  • Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Multiple Myeloma Companies- CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
  • Multiple Myeloma Pipeline Therapies- TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.

 

Dive deep into rich insights for new drugs for Multiple Myeloma treatment, Visit @ Multiple Myeloma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Multiple myeloma Executive Summary
  3. Multiple myeloma Overview
  4. Multiple myeloma Pipeline Therapeutics
  5. Multiple myeloma Therapeutic Assessment
  6. Multiple myeloma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Venetoclax: AbbVie
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. PHE885: Novartis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ONC 201: Oncoceutics
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. TNB 383B: TeneoBio
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Multiple myeloma Companies
  21. Multiple myeloma Products
  22. Multiple myeloma Unmet Needs
  23. Multiple myeloma Market Drivers and Barriers
  24. Multiple myeloma Future Perspectives and Conclusion
  25. Multiple myeloma Analyst Views
  26. Multiple myeloma Companies
  27. Appendix

 

For further information on the Multiple Myeloma pipeline therapeutics, reach out to Multiple Myeloma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Categories